Omnicell (NASDAQ:OMCL) Reaches New 12-Month Low at $25.45

Omnicell, Inc. (NASDAQ:OMCL) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $25.45 and last traded at $25.73, with a volume of 13511 shares traded. The stock had previously closed at $26.22.

Analysts Set New Price Targets

Separately, Benchmark reissued a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.20.

Omnicell Stock Performance

The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $29.44 and a 200 day simple moving average of $30.55.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.17. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. The company had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million. On average, sell-side analysts anticipate that Omnicell, Inc. will post 0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its stake in shares of Omnicell by 321,488.8% in the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock worth $39,814,000 after acquiring an additional 1,057,698 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Omnicell by 15.1% in the third quarter. Vanguard Group Inc. now owns 5,137,084 shares of the company’s stock worth $231,374,000 after acquiring an additional 674,824 shares during the last quarter. Norges Bank acquired a new stake in shares of Omnicell in the fourth quarter worth $18,802,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Omnicell by 12,425.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 482,488 shares of the company’s stock worth $21,731,000 after acquiring an additional 478,636 shares during the last quarter. Finally, Assenagon Asset Management S.A. acquired a new stake in shares of Omnicell in the fourth quarter worth $13,687,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.